Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into ...

Rallybio (RLYB) announced that it received an equity milestone payment of $12.5M from Recursion Pharmaceuticals (RXRX). The milestone payment was ...

Recursion Pharmaceuticals, Inc. ( NASDAQ: RXRX) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 4:05 PM EDT ...

Recursion will also receive an additional $30 million upfront payment from Bayer to develop new treatments for chronic scar tissue, or fibrotic, diseases of the lung, kidneys and heart.

Insitro, Firefly Bio and Superluminal Medicines are among the first participants in Lilly’s “TuneLabs” platform, which the ...

Self-Referential Large Models: Recursive Self-Enhancement in Code Generation ...

Recursion, Exscientia, and AI drug discovery’s moment of truth Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger.

According to data compiled by S&P Global Market Intelligence, Recursion Pharmaceuticals (NASDAQ: RXRX) stock was shedding more than 17% of its value week-to-date as of Thursday night.

Recursion Pharmaceuticals Inc. research and ratings by Barron's. View RXRX revenue estimates and earnings estimates, as well as in-depth analyst breakdowns.

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...